Origin Agritech Held Transgenic Breeding Seminar and Announces Partnerships with 12 Leading Agricultural Companies
BEIJING, Jan. 17, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced the signing of cooperation agreements (the "agreements") with 12 prominent agricultural companies, including Beidahuang Kenfeng Seed Co., Ltd. and Denong Seed Co., Ltd. The Agreements were formalized during the Company's "Corn Smart Plant Type & Transgenic...
GROWNSY LAUNCHES NEW BABY BOTTLE WASHER DESIGNED TO SAVE TIME FOR MODERN PARENTS
NEW YORK, Jan. 17, 2025 /PRNewswire/ -- GROWNSY, the brand dedicated to supporting new parents with cutting-edge and thoughtfully curated products, today announces the launch of the Baby Bottle Washer. This efficient appliance is the latest addition from the brand, designed to make life easier for busy modern parents everywhere. With the touch of...
Hanwha Life Launches ‘Mobile Family Center’ in Indonesia to Strengthen Community-Centered Mental Health Support for Women and Children
Following the launch of "Digital Family Center" last year, "Mobile Family Center" is now open Provides on-site psychological and self-reliance counseling for women and children facing difficulties at home Over a decade of consistent family-focused social contribution activities, building strong community trust JAKARTA, Indonesia, Jan. 17, 2025 /PRNewswire/ -- Hanwha Life announced that, on January 16, it handed over...
Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
SHANGHAI, Jan. 17, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that Senaparib Capsules (派舒宁®）has received marketing authorization in China from National Medical Products Administration (NMPA) as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III...
New study highlights effectiveness and cost benefits of Myriad™ in lower limb salvage surgeries.
AUCKLAND, New Zealand, Jan. 17, 2025 /PRNewswire/ -- New Zealand headquartered soft tissue regeneration company Aroa Biosurgery recently announced the publication of further strong clinical evidence reinforcing both efficacy and cost benefits of its AROA ECM™ technology when used in high-risk limb salvage surgery. Conducted between May 2022 and April 2023, the single site prospective clinical study included a total...
Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, and Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm, 002755.SZ), jointly announce that China's National Medical Products Administration (NMPA)...
LOTTE BIOLOGICS to Present at the 2025 J.P. Morgan Healthcare Conference
New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on "Advancing as a Global CDMO Leader" Unveiling of Next-Generation ADC Platform 'SoluFlex Link': Enabling High-Potency, High-Yield ADC Development and Manufacturing Incheon Songdo Bio Campus Plant 1 Under Construction, Targeting Commercial Production by 2027 SEOUL, South Korea, Jan....
Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference
Advancing into new stage of sustainable growth and global innovation SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, participated in the 43rd Annual J.P. Morgan...
Illuccix® Receives European Approval
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted...
Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States
TAMPA, Fla., Jan. 17, 2025 /PRNewswire/ -- Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrolment of the first patient in the "MAGICAL BTK" (Randomized Controlled Trial of MagicTouch PTA – Sirolimus Coated Balloon Versus Standard Balloon Angioplasty in the Treatment of Below The...
